Accessibility Menu
Corvus Pharmaceuticals Stock Quote

Corvus Pharmaceuticals (NASDAQ: CRVS)

$7.18
(-0.3%)
-0.02
Price as of October 22, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$7.18
Daily Change
(-0.3%) $0.02
Day's Range
$6.81 - $7.43
Previous Close
$7.18
Open
$7.15
Beta
1.17
Volume
873,271
Average Volume
709,637
Market Cap
536.5M
Market Cap / Employee
$7.20M
52wk Range
$2.54 - $10
Revenue
-
Gross Margin
-
Dividend Yield
N/A
EPS
-$1.02
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Corvus Pharmaceuticals Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
CRVS-7.35%+81.31%+12.64%-49%
S&P+14.5%+93.32%+14.09%+229%

Corvus Pharmaceuticals Company Info

Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in Burlingame, CA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$0.00M0.0%
Gross Profit-$0.03M-38.1%
Market Cap$308.46M170.9%
Market Cap / Employee$9.95M0.0%
Employees3110.7%
Net Income-$8.00M-87.7%
EBITDA-$10.23M-73.0%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$14.69M-1.0%
Accounts Receivable$0.09M145.7%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$0.73M0.0%
Short Term Debt$0.36M-49.3%

Ratios

Q2 2025YOY Change
Return On Assets-58.61%-21.7%
Return On Invested Capital-75.83%-24.5%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$5.89M-7.5%
Operating Free Cash Flow-$5.78M-5.4%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book6.4526.986.635.53106.65%
Price to Tangible Book Value6.4526.986.635.53106.66%
Enterprise Value to EBITDA-42.97-38.94-19.79-23.24121.23%
Return on Equity-200.5%-174.9%-100.1%-68.7%52.89%
Total Debt$0.35M$1.12M$1.15M$1.08M54.71%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.